The overall goal of this project is to determine whether common sleep disturbance patterns, sleep continuity disturbance (SCD) and Sleep Fragmentation (SF), alter cerebral study drug receptor availability, drug-based analgesia, and drug abuse liability. The investigators specifically aim to: 1) evaluate whether experimental SCD and/or SF alter resting or pain-evoked receptor binding potential in brain regions associated with pain inhibition; 2) examine whether SCD and/or SF alters the analgesic response and abuse liability profile of a study medication; and 3) determine whether receptor binding potentials in brain regions of interest are associated with study medication analgesia and abuse liability. The investigators will also evaluate the extent to which associations differ by sleep condition or sex.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percent change in receptor binding potential from PET scan
Timeframe: Up to 90 minutes on Day 3 of inpatient visit
Withdrawal Latency measured in seconds during Cold Pressor Pain Tolerance test
Timeframe: Up to 270 minutes post-medication administration
Drug Effects as assessed by the Visual Analog Scale
Timeframe: Up to 270 minutes post-medication administration
The monetary valuation in dollars of the study medication as assessed by the Drug or Money Multiple Choice Questionnaire
Timeframe: 150 minutes after final dose administration